MKI67 and neoplasm: The anti-cancer capacity was documented as tumor volume reduction, decreased expression levels of Ki-67 (a marker of proliferation), cluster of differentiation 31 (CD-31), phospho-Akt, P-MAPK, phosphorylated glycogen synthase kinase-3 beta (P-GSK3β) and phosphorylated fork-head box class O 3α (P-FoxO3α) [99].